Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Decrease in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 15,105 shares, a drop of 72.2% from the December 31st total of 54,264 shares. Based on an average trading volume of 64,767 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the shares of the stock are short sold. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 64,767 shares, the short-interest ratio is currently 0.2 days.

Radiopharm Theranostics Stock Performance

Shares of NASDAQ RADX traded up $0.06 during mid-day trading on Wednesday, reaching $4.98. 21,728 shares of the company’s stock were exchanged, compared to its average volume of 48,964. Radiopharm Theranostics has a 52-week low of $3.50 and a 52-week high of $16.25. The company’s 50-day moving average is $5.04 and its 200-day moving average is $5.35.

Hedge Funds Weigh In On Radiopharm Theranostics

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. raised its position in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,000 shares of the company’s stock after acquiring an additional 8,000 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.20% of Radiopharm Theranostics worth $88,000 as of its most recent SEC filing.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Thursday, January 22nd. B. Riley reaffirmed a “buy” rating and issued a $16.00 price target (up from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th. Finally, Wall Street Zen cut Radiopharm Theranostics to a “strong sell” rating in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $15.33.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.